Table 2.
Average duration of treatment and hospital stay (+/− standard deviation) for eligible subjects and survivors versus treatment group.
| All eligible neonates | Nasal Oxygen | bCPAP |
Transitioned from nasal oxygen to bCPAP |
| Average hospital stay (days) | 9.10 (9.70) | 14.13 (10.87) | 22.00 (14.14) |
| Average time from study entry to treatment with bCPAP (days) | NA | 0.19 (0.42) | 3.11 (3.18) |
| Average total time on treatment (days) | 4.00 (4.37) | 6.91 (5.37) | 13.94 (11.45) |
| Average time receiving nasal oxygen (days) | 4.00 (4.37) | 1.84 (3.04) | 9.83 (9.68) |
| Average time receiving bCPAP (days) | NA | 5.07 (3.66) | 4.11 (2.87) |
| Survivors | Nasal Oxygen | bCPAP |
Transitioned from nasal oxygen to bCPAP |
| Average hospital stay (days) | 13.27 (11.00) | 18.89 (9.60) | 27.57 (10.83) |
| Average time from study entry to treatment with bCPAP (days) | NA | 0.27 (0.49) | 3.86 (3.24) |
| Average total time on treatment (days) | 3.59 (3.05) | 8.69 (5.41) | 17.36 (10.77) |
| Average time receiving nasal oxygen (days) | 3.59 (3.05) | 2.58 (3.36) | 12.43 (9.50) |
| Average time receiving bCPAP (days) | NA | 6.11 (3.72) | 4.93 (2.73) |
doi:10.1371/journal.pone.0086327.t002